Neurosense Net Interest Income vs Ebitda Analysis

NRSN Stock

USD 0.86 0.07 7.53%

Neurosense Therapeutics financial indicator trend analysis is infinitely more than just investigating Neurosense Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurosense Therapeutics is a good investment. Please check the relationship between Neurosense Therapeutics Net Interest Income and its Ebitda accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.

Net Interest Income vs Ebitda

Net Interest Income vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurosense Therapeutics Net Interest Income account and Ebitda. At this time, the significance of the direction appears to have very week relationship.

The correlation between Neurosense Therapeutics' Net Interest Income and Ebitda is 0.22. Overlapping area represents the amount of variation of Net Interest Income that can explain the historical movement of Ebitda in the same time period over historical financial statements of Neurosense Therapeutics, assuming nothing else is changed. The correlation between historical values of Neurosense Therapeutics' Net Interest Income and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Interest Income of Neurosense Therapeutics are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Net Interest Income i.e., Neurosense Therapeutics' Net Interest Income and Ebitda go up and down completely randomly.

Correlation Coefficient

0.22

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Net Interest Income

The difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities.

Ebitda

Most indicators from Neurosense Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurosense Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.As of the 15th of December 2024, Enterprise Value is likely to grow to about 12.9 M, while Selling General Administrative is likely to drop about 3.3 M.

Neurosense Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment
Total Assets		0.55	0.46	0.74	0.81	0.5	-0.95	-0.52	0.33	0.95	0.42	-0.84	1.0	0.87	0.44	0.78	-0.51	0.95	0.72	0.6	0.74	0.5	1.0	0.85	-0.25	0.77
Other Current Liab	0.55		0.99	-0.14	0.93	0.82	-0.39	-1.0	0.97	0.43	0.79	-0.89	0.52	0.82	0.97	0.71	-0.93	0.75	0.9	0.98	-0.14	0.83	0.53	0.03	-0.85	0.8
Total Current Liabilities	0.46	0.99		-0.24	0.89	0.79	-0.3	-0.99	0.99	0.35	0.77	-0.84	0.43	0.76	0.97	0.67	-0.92	0.67	0.86	0.97	-0.24	0.81	0.44	-0.07	-0.89	0.75
Total Stockholder Equity	0.74	-0.14	-0.24		0.22	0.06	-0.77	0.15	-0.38	0.72	-0.01	-0.3	0.75	0.4	-0.21	0.33	0.07	0.55	0.2	-0.09	1.0	0.04	0.75	0.98	0.46	0.33
Net Tangible Assets	0.81	0.93	0.89	0.22		0.79	-0.68	-0.92	0.82	0.71	0.73	-0.99	0.79	0.96	0.86	0.85	-0.87	0.93	0.95	0.95	0.22	0.8	0.8	0.39	-0.69	0.9
Property Plant And Equipment Net	0.5	0.82	0.79	0.06	0.79		-0.27	-0.85	0.72	0.25	1.0	-0.8	0.46	0.72	0.89	0.47	-0.96	0.74	0.91	0.72	0.06	1.0	0.48	0.14	-0.45	0.79
Net Debt	-0.95	-0.39	-0.3	-0.77	-0.68	-0.27		0.36	-0.19	-0.99	-0.17	0.73	-0.95	-0.81	-0.22	-0.83	0.27	-0.84	-0.58	-0.49	-0.77	-0.27	-0.95	-0.89	0.13	-0.69
Retained Earnings	-0.52	-1.0	-0.99	0.15	-0.92	-0.85	0.36		-0.96	-0.39	-0.83	0.88	-0.49	-0.81	-0.98	-0.69	0.95	-0.74	-0.91	-0.97	0.15	-0.87	-0.51	-0.02	0.82	-0.82
Accounts Payable	0.33	0.97	0.99	-0.38	0.82	0.72	-0.19	-0.96		0.24	0.72	-0.76	0.3	0.67	0.95	0.6	-0.87	0.56	0.78	0.95	-0.38	0.75	0.31	-0.21	-0.92	0.67
Cash	0.95	0.43	0.35	0.72	0.71	0.25	-0.99	-0.39	0.24		0.16	-0.74	0.95	0.82	0.26	0.84	-0.29	0.84	0.58	0.54	0.72	0.26	0.95	0.85	-0.22	0.68
Non Current Assets Total	0.42	0.79	0.77	-0.01	0.73	1.0	-0.17	-0.83	0.72	0.16		-0.74	0.38	0.65	0.88	0.39	-0.95	0.67	0.87	0.68	-0.01	0.99	0.39	0.06	-0.44	0.74
Non Currrent Assets Other	-0.84	-0.89	-0.84	-0.3	-0.99	-0.8	0.73	0.88	-0.76	-0.74	-0.74		-0.82	-0.97	-0.82	-0.86	0.84	-0.96	-0.95	-0.91	-0.3	-0.81	-0.83	-0.46	0.6	-0.9
Cash And Short Term Investments	1.0	0.52	0.43	0.75	0.79	0.46	-0.95	-0.49	0.3	0.95	0.38	-0.82		0.86	0.4	0.77	-0.47	0.93	0.69	0.57	0.75	0.46	1.0	0.86	-0.23	0.75
Net Receivables	0.87	0.82	0.76	0.4	0.96	0.72	-0.81	-0.81	0.67	0.82	0.65	-0.97	0.86		0.71	0.94	-0.74	0.97	0.94	0.86	0.4	0.73	0.86	0.56	-0.5	0.96
Common Stock Shares Outstanding	0.44	0.97	0.97	-0.21	0.86	0.89	-0.22	-0.98	0.95	0.26	0.88	-0.82	0.4	0.71		0.55	-0.98	0.67	0.87	0.91	-0.21	0.9	0.42	-0.08	-0.81	0.73
Non Current Liabilities Total	0.78	0.71	0.67	0.33	0.85	0.47	-0.83	-0.69	0.6	0.84	0.39	-0.86	0.77	0.94	0.55		-0.53	0.84	0.8	0.81	0.33	0.5	0.78	0.52	-0.49	0.85
Inventory	-0.51	-0.93	-0.92	0.07	-0.87	-0.96	0.27	0.95	-0.87	-0.29	-0.95	0.84	-0.47	-0.74	-0.98	-0.53		-0.74	-0.91	-0.85	0.07	-0.96	-0.48	-0.04	0.69	-0.77
Other Current Assets	0.95	0.75	0.67	0.55	0.93	0.74	-0.84	-0.74	0.56	0.84	0.67	-0.96	0.93	0.97	0.67	0.84	-0.74		0.91	0.77	0.55	0.74	0.94	0.68	-0.39	0.91
Other Stockholder Equity	0.72	0.9	0.86	0.2	0.95	0.91	-0.58	-0.91	0.78	0.58	0.87	-0.95	0.69	0.94	0.87	0.8	-0.91	0.91		0.88	0.2	0.92	0.7	0.34	-0.54	0.96
Total Liab	0.6	0.98	0.97	-0.09	0.95	0.72	-0.49	-0.97	0.95	0.54	0.68	-0.91	0.57	0.86	0.91	0.81	-0.85	0.77	0.88		-0.09	0.74	0.59	0.1	-0.86	0.81
Net Invested Capital	0.74	-0.14	-0.24	1.0	0.22	0.06	-0.77	0.15	-0.38	0.72	-0.01	-0.3	0.75	0.4	-0.21	0.33	0.07	0.55	0.2	-0.09		0.04	0.75	0.98	0.46	0.33
Property Plant And Equipment Gross	0.5	0.83	0.81	0.04	0.8	1.0	-0.27	-0.87	0.75	0.26	0.99	-0.81	0.46	0.73	0.9	0.5	-0.96	0.74	0.92	0.74	0.04		0.47	0.12	-0.47	0.8
Total Current Assets	1.0	0.53	0.44	0.75	0.8	0.48	-0.95	-0.51	0.31	0.95	0.39	-0.83	1.0	0.86	0.42	0.78	-0.48	0.94	0.7	0.59	0.75	0.47		0.86	-0.24	0.76
Net Working Capital	0.85	0.03	-0.07	0.98	0.39	0.14	-0.89	-0.02	-0.21	0.85	0.06	-0.46	0.86	0.56	-0.08	0.52	-0.04	0.68	0.34	0.1	0.98	0.12	0.86		0.29	0.47
Common Stock	-0.25	-0.85	-0.89	0.46	-0.69	-0.45	0.13	0.82	-0.92	-0.22	-0.44	0.6	-0.23	-0.5	-0.81	-0.49	0.69	-0.39	-0.54	-0.86	0.46	-0.47	-0.24	0.29		-0.44
Property Plant Equipment	0.77	0.8	0.75	0.33	0.9	0.79	-0.69	-0.82	0.67	0.68	0.74	-0.9	0.75	0.96	0.73	0.85	-0.77	0.91	0.96	0.81	0.33	0.8	0.76	0.47	-0.44

Click cells to compare fundamentals

Neurosense Therapeutics Account Relationship Matchups

Pair Trading with Neurosense Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neurosense Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neurosense Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Neurosense Stock

0.72	VALN	Valneva SE ADR	Pair Corr
0.79	ERNA	Eterna Therapeutics	Pair Corr

Moving against Neurosense Stock

0.75	DYAI	Dyadic International	Pair Corr
0.55	ESPR	Esperion Therapeutics	Pair Corr
0.55	BMY	Bristol Myers Squibb	Pair Corr
0.36	DNA	Ginkgo Bioworks Holdings	Pair Corr
0.33	FLGC	Flora Growth Corp	Pair Corr

The ability to find closely correlated positions to Neurosense Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neurosense Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neurosense Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neurosense Therapeutics to buy it.

The correlation of Neurosense Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neurosense Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neurosense Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Neurosense Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Neurosense Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neurosense Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neurosense Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neurosense Therapeutics Stock:

How To Invest In Neurosense

Details

Is Neurosense Stock a good investment?

Details

What is Neurosense Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurosense Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

To learn how to invest in Neurosense Stock, please use our How to Invest in Neurosense Therapeutics guide.

You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurosense Therapeutics. If investors know Neurosense will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurosense Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.65)

Return On Assets

(1.51)

Return On Equity

(4.95)

The market value of Neurosense Therapeutics is measured differently than its book value, which is the value of Neurosense that is recorded on the company's balance sheet. Investors also form their own opinion of Neurosense Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Neurosense Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurosense Therapeutics' market value can be influenced by many factors that don't directly affect Neurosense Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurosense Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurosense Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurosense Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurosense Net Interest Income vs Ebitda Analysis

Net Interest Income vs Ebitda

Net Interest Income vs Ebitda Correlation Analysis

Correlation Coefficient

Net Interest Income

Ebitda

Neurosense Therapeutics fundamental ratios Correlations

Neurosense Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pair Trading with Neurosense Therapeutics

Moving together with Neurosense Stock

Moving against Neurosense Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Stockholder Equity
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments

Retained Earnings	- 1.0	Other Current Liab
Cash	- 0.99	Net Debt
Non Currrent Assets Other	- 0.99	Net Tangible Assets
Retained Earnings	- 0.99	Total Current Liabilities
Inventory	- 0.98	Common Stock Shares Outstanding
Common Stock Shares Outstanding	- 0.98	Retained Earnings